New technologies for diagnosing active TB: the VANTDET diagnostic accuracy study

Alice Halliday,1,2 Pooja Jain,1,3† Long Hoang,1† Robert Parker,1† Mica Tolosa-Wright,1† Tereza Masonou,1 Nathan Green,4,5,6,7 Long Hoang,1† Mica Tolosa-Wright,1† Tereza Masonou,1 Nathan Green,4,5,6,7 Aime Boakye,1,3 Yemisi Takwoingi,8,9 Shea Hamilton,10 Vinay Mandagere,1 Anastasia Fries,1 Lachlan Coin,11 Jon Deeks,8,9 Peter J White,4,5,6,7 Michael Levin,10 Peter Beverley,1 Onn Min Kon1,3,12 and Ajit Lalvani1,3*

1TB Research Centre, National Heart and Lung Institute, Imperial College London, London, UK
2Cellular and Molecular Medicine, University of Bristol, Bristol, UK
3National Institute for Health Research, Health Protection Research Unit in Respiratory Infection, Imperial College London, London, UK
4National Institute for Health Research, Health Protection Research Unit in Modelling Methodology, Imperial College London, London, UK
5Medical Research Council, Centre for Global Infectious Disease Analysis, Imperial College London, London, UK
7Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
8Test Evaluation Research Group, Institute of Applied Health Research, University of Birmingham, Birmingham, UK
9National Institute for Health Research, Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK
10Paediatric Infectious Diseases Group, Division of Medicine, Imperial College London, London, UK
11Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia
12St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, UK

*Corresponding author a.lalvani@imperial.ac.uk
†These authors contributed equally
Declared competing interests of authors: Alice Halliday has a patent pending entitled 'A cellular immune signature for risk stratification of latent tuberculosis infection'. Robert Parker reports having the following patents pending: 1719853.2 and 2017904359. Lachlan Coin reports having the following patents pending: WO2014067943A1 and US20150284780A1. In addition, Lachlan Coin has one patent issued: EP2914740B1. Jon Deeks reports grants from National Institute for Health Research (NIHR) during the conduct of the study and receipt of a NIHR Senior Investigator Emeritus award and that he is supported by the NIHR Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust and University of Birmingham. Peter White reports grants from the Medical Research Council and the NIHR during the conduct of the study, and grants from Otsuka Pharmaceutical (Tokyo, Japan) outside the submitted work. Onn Min Kon is chairperson of the UK Joint Tuberculosis Committee. Ajit Lalvani reports issued patents underpinning interferon gamma release assays (IGRAs) and next-generation IGRAs, some of which were assigned by the University of Oxford to Oxford Immunotec Global plc (Abingdon, UK), resulting in royalty entitlements for the University of Oxford and Ajit Lalvani. Ajit Lalvani is also inventor of issued and pending unlicensed patents underpinning flow-cytometric diagnosis of tuberculosis.
Plain English summary

Globally, tuberculosis (TB) is the most deadly infectious disease, with 10 million cases each year, resulting in 1.3 million deaths. TB is caused by a bacterium that is transmitted from an individual with TB disease of the lungs to another person by coughing. There are several diagnostic tests for TB, most of which detect the presence of the bacteria in clinical samples. However, these tests fail to detect all TB patients, particularly when there is a small number of bacteria present at the site of disease and/or it is difficult to get a sample. This means that some wait a long time for a final diagnosis and incur a delay before starting treatment, or else are given TB treatment without a clear diagnosis. New and improved diagnostic tests that allow for the rapid detection of all active TB cases would greatly improve patient care.

Recently, scientists have found several new approaches to testing for TB disease that use new technologies to measure the immune response in blood samples. In previous studies, these new technologies were able to distinguish between TB and other diseases that appear clinically similar to TB. In this project we aimed to validate these new technologies using samples from patients with the full range of TB disease, including those who test negative on the current tests. Overall, we found that the new technologies worked less well than previously reported. Importantly, they were unable to detect all of the TB patients who tested positive on the current tests. Owing to the poor accuracy for diagnosing all TB patients, and the high cost of these new tests, we found that none of the new tests would be cost-effective for use on all individuals who have suspected TB. However, in the hard-to-diagnose patient groups, for whom there are currently no rapid tests available, some of the new tests may be useful if used alongside existing tests.
Efficacy and Mechanism Evaluation

ISSN 2050-4365 (Print)
ISSN 2050-4373 (Online)

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full EME archive is freely available to view online at www.journalslibrary.nihr.ac.uk/eme. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

**Criteria for inclusion in the Efficacy and Mechanism Evaluation journal**
Reports are published in Efficacy and Mechanism Evaluation (EME) if (1) they have resulted from work for the EME programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

**EME programme**
The Efficacy and Mechanism Evaluation (EME) programme funds ambitious studies evaluating interventions that have the potential to make a step-change in the promotion of health, treatment of disease and improvement of rehabilitation or long-term care. Within these studies, EME supports research to improve the understanding of the mechanisms of both diseases and treatments.

The programme supports translational research into a wide range of new or repurposed interventions. These may include diagnostic or prognostic tests and decision-making tools, therapeutics or psychological treatments, medical devices, and public health initiatives delivered in the NHS.

The EME programme supports clinical trials and studies with other robust designs, which test the efficacy of interventions, and which may use clinical or well-validated surrogate outcomes. It only supports studies in man and where there is adequate proof of concept. The programme encourages hypothesis-driven mechanistic studies, integrated within the efficacy study, that explore the mechanisms of action of the intervention or the disease, the cause of differing responses, or improve the understanding of adverse effects. It funds similar mechanistic studies linked to studies funded by any NIHR programme.

The EME programme is funded by the Medical Research Council (MRC) and the National Institute for Health Research (NIHR), with contributions from the Chief Scientist Office (CSO) in Scotland and National Institute for Social Care and Health Research (NISCHR) in Wales and the Health and Social Care Research and Development (HSC R&D), Public Health Agency in Northern Ireland.

**This report**
The research reported in this issue of the journal was funded by the EME programme as project number 12/65/27. The contractual start date was in March 2014. The final report began editorial review in April 2018 and was accepted for publication in December 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The EME editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research. The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, the MRC, NETSCC, the EME programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the EME programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2021. This work was produced by Halliday et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Professor of Digital Health Care, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Senior Scientific Adviser (Evidence Use), Wessex Institute, University of Southampton, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Emeritus Professor of Wellbeing Research, University of Winchester, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk